CEL-SCI Corporation reported its financial results for the three months ended June 30, 2025, on August 14, 2025. The company recorded a net loss available to common shareholders of $5.7 million for the quarter, compared to $7.5 million in the prior year period.
Basic and diluted net loss per common share was $1.36 for the three months ended June 30, 2025, a significant reduction compared to $4.18 for the three months ended June 30, 2024. This improvement reflects ongoing cost-cutting measures.
CEO Geert Kersten continues to work without taking a salary, demonstrating his deep commitment to the company and Multikine’s potential to significantly improve patient outcomes. The company noted accelerating commercial and regulatory momentum for Multikine, particularly in Saudi Arabia.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.